Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289846 · ClinicalTrials.gov registry record · Phase 2
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT02289846 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT02289846, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
Interventions
- DRUG Matching Placebo
- DRUG IW-9179
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289846
The ClinicalTrials.gov registry entry for NCT02289846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02289846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289846 about?
NCT02289846 is a clinical study titled "Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)". The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
What is the current status of trial NCT02289846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2014-10. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02289846?
The interventions under investigation include: Matching Placebo (DRUG), IW-9179 (DRUG).
Who is sponsoring clinical trial NCT02289846?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.